Thank you Free; It's a beautiful thing both for revs. and earnings. Unlike if Dacogen were a new product and distributed by different partners the AML approval simply adds more total revs for their existing partner which kicks in the turbo multiplier for Astex royalties. There's more than meets the eye to this EU approval.
The 30% is because the $200M level is ALL worldwide sales correct? Does not matter if J&J or Eisai is the seller.
Also, there is a $5M milestone payment for approval and a $5M payment for $100M in sales on AML. Do you know what the other $7.5 milstone payment is triggered by? Press release today made mention of $17.5M in payments.
The other $7.5M is when they get Japan approval, I believe. I guess the street wants to see revenues first.
I'm looking down the road, if SGI-110 gets approval, the full market maybe there for the taking. WW sales over $1b and ASTX doesn't have to share a dime of it. Hopefully it points in that direction in December.